The inspected humanin study tested protection against neurotoxicity from multiple Alzheimer's-disease-related genetic mutations and beta-amyloid peptides, and compared native humanin with a modified analogue (S14G-humanin), in laboratory cell models. It does not establish prevention or treatment of dementia, or longer life, in humans.[1]
- Effects of modified analogues cannot automatically be attributed to every product labeled humanin; the abstract itself found the modified analogue more broadly protective than native humanin in these experiments.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Freshly reread the abstract via NCBI E-utilities; confirmed the multiple gene-mutant/amyloid insults tested and the native-vs-analogue comparison, and revised the claim text to reflect this precisely. No qualified clinical review.